The mission of our lab is to discover MRI biomarkers that identify pathological changes leading to clinical deterioration in persons with multiple sclerosis

The Bagnato lab has two main complementary research goals.

First: we aim to understand the pathobiology of multiple sclerosis (MS) and the substrate of its associated symptoms and disability using non-invasive imaging methods such as magnetic resonance imaging (MRI). Second: we aim to identify a surrogate marker of neurodegeneration that can be used as measure of outcome during both natural history and experimental clinical trials, assessing neuroprotection and repair in patients with MS.

To this end, a major focus of our lab is to identify, characterize and quantify disease mechanisms otherwise hidden on conventional clinical imaging. These pathological processes include microglia activation, myelin and axonal injury.

By working in close collaboration with basic scientists and clinicians, our work starts with the histopathological validation of novel MRI methods using postmortem human samples and ends with the application of these innovative and unique techniques in patients with MS.

The Bagnato lab collaborate with several other labs around the world and is part of the North American Imaging in MS Cooperative (NAIMS).